Though survival outcomes of patients with HER2-positive breast cancer have greatly improved by adding pertuzumab to trastuzumab and chemotherapy, long-term toxicities, mainly cardiotoxicities, have emerged as a particular concern [3]. Here, ERBB2 is linked to breast carcinoma.